SUBMIT YOUR RESEARCH
Saudi Journal of Pathology and Microbiology (SJPM)
Volume-5 | Issue-03 | 167-172
Original Research Article
Study of Hematological Parameters in End Stage Renal Disease Patients; Those on Regular Hemodialysis as Renal Replacement Therapy
Milind Kesarkhane, Rekha M Haravi, Shreekant Kittur, Archana Dambal
Published : March 7, 2020
DOI : 10.36348/sjpm.2020.v05i03.003
Abstract
In India only few studies are focused on hematological parameters in End Stage Renal Disease (ESRD). This study was undertaken to study haematological parameters in ESRD patients undergoing regular haemodialysis and to compare haematological parameters in these patients before and after haemodialysis. Chronic Kidney Disease is a global public health problem responsible for high morbidity and mortality with greater burden of cost of care especially in developing countries like India. Adult patients with ESRD undergoing regular haemodialysis at Tertiary Care Hospital, Hemodialysis unit were included in the study, irrespective of their etiology. ESRD was diagnosed by nephrologist with creatinine clearance < 15 ml/min calculated by Cockcroft-Gault equation, biochemical and radiological investigations. With proper aseptic precautions, 5 ml venous blood collected in EDTA vacutainer just before starting haemodialysis and after completion of haemodialysis. Mean age of the patients was 41.03±12.6 years with maximum number of male patients with diabetes mellitus with hypertension being most common cause for ESRD. There was statistically significant difference in post haemodialysis value as compared with predialysis value for haemoglobin concentration, hematocrit, RBC count and platelet count. Globally, the dialysis-monitoring strategy is principally based on measurement of biochemical parameters before and after each session of dialysis. This study indicate that most haematological parameters in Hemodialysis patients are significantly altered both pre and post haemodialysis. Thus, monitoring the haematological parameters may help in deciding erythropoietin stimulating agent dose, preventing possible complications and consequently reducing the mortality/morbidity rate in ESRD patients on haemodialysis.
Scholars Middle East Publishers
Browse Journals
Payments
Publication Ethics
SUBMIT ARTICLE
Browse Journals
Payments
Publication Ethics
SUBMIT ARTICLE
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© Copyright Scholars Middle East Publisher. All Rights Reserved.